EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Dalpiciclib combined with endocrine therapy for patients with HR+/HER2− metastatic breast cancer: a multicenter real-world study

Xuelian Chen iD, Lin Lin, Guangning He, Guanghui Ren, Jiayi Huang, Liping Chen, Xiaofeng Lan, Xiaofeng Xie, Lin Song, Xue Bai, Caiwen Du

Therapeutic Advances in Medical Oncology · 2026-07 · 18

DOI: 10.1177/17588359261467382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 29.07.2026. Verfasst von Xuelian Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Acad…. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: sanming project of medicine in shenzen municipality, national cancer center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dalpiciclib is the latest cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved in China. Real-world data regarding the efficacy and safety of dalpiciclib for metastatic breast cancer (MBC) are still insufficient.

Objectives

This study aims to investigate the real-world outcomes of dalpiciclib in a more heterogeneous population of patients with MBC.

Design

We retrospectively collected data of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) MBC patients who received dalpiciclib plus endocrine therapy (ET) between January 2022 to March 2025 from four clinical centers in South China.

Methods

Demographic characteristics and clinical data were collected. Real-world progression-free survival (rwPFS), objective response rate (ORR), and safety profiles were analyzed.

Results

In total, 160 patients were included. The median follow-up time was 17.6 months (95% confidence interval (CI): 15.0–20.2). The estimated overall median rwPFS was 20.6 months (95% CI: 12.4–28.8), and the ORR was 17.5% (28/160) for the entire cohort. Subgroup analysis showed that the median rwPFS was 26.7 months in patients receiving first-line dalpiciclib plus ET, compared with 13.8 months in those receiving second- or later-line treatment. The median rwPFS for patients with brain metastases (BMs; n = 13) was 14.8 months (95% CI: 4.0–25.6), and the median rwPFS for patients treated by prior CDK4/6 inhibitors ( n = 33) was 7.2 months. Stratified Cox regression analysis revealed that the presence of de novo metastatic disease was an independent factor for an increased risk of disease progression (hazard ratio 0.47, 95% CI: 0.25–0.91, p = 0.025). Hematologic toxicity was the most frequent adverse event associated with dalpiciclib treatment.

Conclusion

In this real-world cohort of HR+/HER2− MBC patients, dalpiciclib plus ET retains its favorable clinical activity. This regimen also showed promising activity in patients with BMs and those previously exposed to CDK4/6 inhibitors.

Schlagwörter

Stichwörter der Autor:innen

CDK4/6 inhibitorsbreast cancerdalpiciclibefficacyreal-world

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Gu…
  • Department of Medical Oncology, The First Affiliated Hospital of Shenzhen University and Shenzhen Second People's Hospital, Shenzhen, Guangdong, China.
  • Department of Breast Surgery, Dongguan People's Hospital, Dongguan, Guangdong, China.
  • Department of Thyroid and Breast Surgery, Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong, China.
  • Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 113rd Baohe Road, Longgang…

ORCID-Profile: Xuelian Chen

Förderung

  • sanming project of medicine in shenzen municipality
  • national cancer center

Zitieren

APA

Chen, X., Lin, L., He, G., Ren, G., Huang, J., Chen, L., Lan, X., Xie, X., Song, L., Bai, X., & Du, C. (2026). Dalpiciclib combined with endocrine therapy for patients with HR+/HER2− metastatic breast cancer: a multicenter real-world study. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261467382

Vancouver

Chen X, Lin L, He G, Ren G, Huang J, Chen L, et al. Dalpiciclib combined with endocrine therapy for patients with HR+/HER2− metastatic breast cancer: a multicenter real-world study. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261467382

BibTeX
@article{Chen2026,
  author = {Chen, Xuelian and Lin, Lin and He, Guangning and Ren, Guanghui and Huang, Jiayi and Chen, Liping and Lan, Xiaofeng and Xie, Xiaofeng and Song, Lin and Bai, Xue and Du, Caiwen},
  title = {Dalpiciclib combined with endocrine therapy for patients with HR+/HER2− metastatic breast cancer: a multicenter real-world study},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261467382}
}
Kostenlos starten →